Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder

This study is ongoing, but not recruiting participants.

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00539773

Purpose

Phase II Trial of concurrent administration of intravesical BCG & Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.

Condition	Intervention
Transitional Carcinoma of Urinary Bladder	Drug: BCG, Interferon

Genetics Home Reference related topics: bladder cancer

MedlinePlus related topics: Bladder Cancer

Drug Information available for: Interferons

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Patients with superficial transitional carcinoma of the urinary bladder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00539773

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:

Shouki Bazarbashi, MD

King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

More Information

Study ID Numbers:	RAC#2011-073
Study First Received:	October 4, 2007
Last Updated:	October 4, 2007
ClinicalTrials.gov Identifier:	NCT00539773
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Cystocele
Interferons
Urinary Bladder Diseases
Urinary Bladder Neoplasms
Urogenital Neoplasms
Carcinoma, Transitional Cell
Urologic Neoplasms

Transitional cell carcinoma
Recurrence
Carcinoma
Urologic Diseases
Urinary tract neoplasm
Neoplasms, Glandular and Epithelial
Bladder neoplasm

Additional relevant MeSH terms:

Anti-Infective Agents
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site

Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009